Centre Hospitalier Régional et Universitaire de Nancy

Running trials

• Recruiting

  Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma

  NCT06485908· Phase 1/2· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  What is the Role of the Exposome in Pulmonary Hypertension

  NCT07172334· Poitiers University Hospital· Source

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· Phase 2· Institut Curie· Source

• Not yet recruiting

  FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

  2026-525763-40-00· Phase 2· French Innovative Leukemia Organization (F.I.L.O.).· Source

• Not yet recruiting

  Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT07739459· Phase 2· The Lymphoma Academic Research Organisation· Source

• Not yet recruiting

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years

  NCT07845994· Phase 3· University Hospital, Angers· Source

• Not yet recruiting

  Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study

  NCT07376447· iVascular S.L.U.· Source

• Recruiting

  Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  2025-523288-39-00· Phase 2· Mediar Therapeutics Inc.· Source

• Not yet recruiting

  Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab

  NCT07836283· Phase 3· University Hospital, Rouen· Source

• Recruiting

  Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

  NCT07323316· Ad scientiam· Source

• Not yet recruiting

  Remote Monitoring and Optimization of Heart Failure Therapy

  NCT07622472· Zoll Medical Corporation· Source

• Not yet recruiting

  Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

  2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source

• Not yet recruiting

  Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial

  2026-526632-39-00· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source

• Not yet recruiting

  Follow-up After Oncological Resection by Endoscopic Colorectal ESD (Endoscopic Submucosal Dissection)

  NCT07871227· University Hospital, Bordeaux· Source

• Recruiting

  Virtual hIStology of Crohn's Disease Ex-vivo Resected Anatomical Lesions

  NCT07413653· Central Hospital, Nancy, France· Source

• Recruiting

  ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

  NCT07545512· University Hospital, Clermont-Ferrand· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Not yet recruiting

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source

• Not yet recruiting

  CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia

  2023-507010-27-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

• Not yet recruiting

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· Phase 2· French Innovative Leukemia Organisation· Source

• Not yet recruiting

  Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?

  NCT07545889· University Hospital, Strasbourg, France· Source

• Not yet recruiting

  OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.

  2025-524003-68-00· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Not yet recruiting

  Real-world Evaluation of Different Endoscopic Biliary Drainage Techniques in Patients With Jaundice of Biliopancreatic Malignant Origin

  NCT07817602· Centre Hospitalier Universitaire de Nīmes· Source

• Not yet recruiting

  Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

  NCT07463768· Phase 2· French Innovative Leukemia Organisation· Source

• Not yet recruiting

  Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Juxtarenal Abdominal Aortic Aneurysm

  NCT07441564· University Hospital, Rouen· Source

• Not yet recruiting

  Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

  NCT07359456· Phase 2· UNICANCER· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· Phase 3· Unicancer· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

  2024-519753-11-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Recruiting

  A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  2025-523670-17-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

  NCT07189325· Phase 3· University Hospital, Montpellier· Source

• Not yet recruiting

  Liquid Biopsy in Early Colorectal Lesions

  NCT07319104· University Hospital, Montpellier· Source

• Recruiting

  The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

  NCT06494878· Phase 3· University of Calgary· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Recruiting

  Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

  NCT07418827· Assistance Publique Hopitaux De Marseille· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

Showing 50 of 398.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers30 recruiting
• Crohn's disease23 recruiting
• Colorectal cancer19 recruiting
• Heart failure19 recruiting
• Lung cancer17 recruiting
• Stroke14 recruiting
• Multiple myeloma13 recruiting
• Multiple sclerosis11 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Acute myeloid leukaemia9 recruiting
• Chronic lymphocytic leukaemia9 recruiting
• Fatty liver disease (MASLD/MASH)9 recruiting
• Pancreatic cancer9 recruiting
• Ulcerative colitis9 recruiting
• Liver and biliary tract cancer8 recruiting
• High blood pressure6 recruiting
• Coronary artery disease5 recruiting
• Epilepsy5 recruiting
• Alzheimer disease4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Follicular lymphoma4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Prostate cancer4 recruiting
• Rheumatoid arthritis4 recruiting
• Atrial fibrillation3 recruiting
• Chronic kidney disease3 recruiting
• Chronic myeloid leukaemia3 recruiting
• COPD3 recruiting
• Dermatomyositis and polymyositis (myositis)3 recruiting
• Kidney cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Myasthenia gravis3 recruiting
• Myelodysplastic syndromes3 recruiting
• Neuroblastoma3 recruiting
• Obesity3 recruiting
• Sarcoma3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• ANCA-associated vasculitis2 recruiting
• Aplastic anaemia2 recruiting
• Brain aneurysm2 recruiting
• Cushing's syndrome2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Glioblastoma2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Lewy body dementia2 recruiting
• Lupus (SLE)2 recruiting
• Meningioma2 recruiting
• Myocarditis2 recruiting
• Obstructive sleep apnoea2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Thyroid cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• ALS (motor neurone disease)1 recruiting
• Amyloidosis1 recruiting
• Ankylosing spondylitis1 recruiting
• Aortic aneurysm1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Barrett's oesophagus1 recruiting
• Bladder cancer1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Cystic fibrosis1 recruiting
• Cytomegalovirus infection1 recruiting
• Diabetic eye disease1 recruiting
• Down syndrome1 recruiting
• Dystonia1 recruiting
• Endometriosis1 recruiting
• Haemophilia1 recruiting
• Head and neck cancer1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Polycystic kidney disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Schizophrenia1 recruiting
• Sjögren's disease1 recruiting
• Turner syndrome1 recruiting
• Type 2 diabetes1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis

  NCT07605741· Central Hospital, Nancy, France· Source

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Not yet recruiting

  Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

  NCT06933966· Phase 2· Centre Leon Berard· Source

• Completed

  A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor

  2024-517987-46-00· Phase 2· Bioprojet Pharma· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis

  NCT06867094· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.

  NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  Experiences and Care Pathways Shared on Social Media Regarding 5 Conditions Causing Chronic Pain

  NCT07871578· Central Hospital, Nancy, France· Source

• Completed

  Quantification With Lutetium-177 on Cadmium-Zinc-Telluride Camera 3D

  NCT06783088· Central Hospital, Nancy, France· Source

• Completed

  Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer

  NCT06461689· Central Hospital, Nancy, France· Source

• Completed

  Comparison of SPECT/CT Perfusion and Volumetric CT Volume

  NCT06600204· Central Hospital, Nancy, France· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· AbbVie· Source

• Completed

  Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

  NCT06614205· Central Hospital, Nancy, France· Source

• Completed

  Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide

  NCT06255249· Central Hospital, Nancy, France· Source

• Completed

  ALS Phase II Study of NX210c

  NCT06365216· Phase 2· Axoltis Pharma· Source

• Completed

  Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer

  2024-512754-16-01· Phase 3· Curium US LLC· Source

• Completed

  Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial

  NCT04667078· Phase 4· Fondation A De Rothschild· Source

• Active, not recruiting

  NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

  NCT06379217· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  PASSPORT

  NCT06274294· Phase 3· Centre Medico Chirurgical Ambroise Pare Hartmann· Source

• Recruiting

  Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

  NCT06122584· Phase 3· ABX advanced biochemical compounds GmbH· Source

• Recruiting

  [18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer

  2023-504026-19-01· Phase 3· Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH· Source

• Completed

  Predictive Factors for a Positive Exercise Bronchial Hyperresponsiveness Test

  NCT07766460· Central Hospital, Nancy, France· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Genentech Inc.· Source

• Completed

  Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy

  2023-509615-92-00· Phase 2· Hopital Fondation Adolphe De Rothschild· Source

• Completed

  Janus Kinase Inhibitors for the Treatment of Acute Severe Ulcerative Colitis

  NCT06449820· Central Hospital, Nancy, France· Source

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

• Terminated

  A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

  NCT06220669· Phase 2· Eli Lilly and Company· Source

• Completed

  Real-life Follow-up of the Physical Activity in Type 1 Diabetes Participants Equipped With an Insulin Pump With Hybrid Closed Loop

  NCT07015970· ISIS Diabete Service· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source

• Completed

  Evaluation of Cardiovascular Risk After Preeclampsia in General Practitioners and Patients

  NCT06059937· Central Hospital, Nancy, France· Source

• Completed

  Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

  NCT06080399· University Hospital, Toulouse· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

• Completed

  Millipede AspiRation for Revascularization in Stroke (MARRS) Study

  NCT05714501· Perfuze· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Completed

  Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

  NCT05923827· Insulet Corporation· Source

• Completed

  Optimizing Treatments for Heart Failure During Hospitalization

  NCT05910437· Central Hospital, Nancy, France· Source

• Completed

  Lung Hyperinflation and Response to Pulmonary Vasodilator Therapy

  NCT06613321· Central Hospital, Nancy, France· Source

• Active, not recruiting

  Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

  NCT05910528· Phase 2· Hoffmann-La Roche· Source

• Completed

  Study Evaluating the Persistence, Efficacy and Tolerability of Methotrexate in Inflammatory Bowel Disease Patients

  NCT05927064· Central Hospital, Nancy, France· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source

• Completed

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· Phase 2· Amgen Inc.· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

  NCT03966651· Phase 1· Institut Claudius Regaud· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy-

  2022-501217-31-00· Phase 2/3· Fondation Franc.Cancerologie Digestive· Source

• Completed

  Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI

  NCT06037343· Central Hospital, Nancy, France· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

  NCT04789850· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

Showing 50 of 138.

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure184 works · 24 trials
• Crohn's disease50 works · 42 trials
• Chronic kidney disease48 works · 7 trials
• Ulcerative colitis46 works · 35 trials
• Aortic stenosis12 works · 0 trials
• Pulmonary arterial hypertension10 works · 8 trials
• Ventricular tachycardia9 works · 1 trial
• Myelodysplastic syndromes9 works · 11 trials
• Dilated cardiomyopathy8 works · 0 trials
• Haemophilia7 works · 5 trials
• High blood pressure5 works · 18 trials
• Lyme disease5 works · 2 trials
• Aplastic anaemia4 works · 2 trials